Background/Objectives: Acetylsalicylic acid (ASA) medication has been suggested to have a beneficial effect on cancer risk and survival. Therefore, this retrospective case–control study investigated the correlation between ASA and HNC in over 11,000,000 patients to investigate the impact of ASA intake on the risk of developing HNC, five-year survival rates, and the likelihood of secondary malignant neoplasms and malignant lymph node involvement.Methods: Retrospective clinical data was retrieved from a federated EHR network. Patients prescribed ASA were assigned to Cohort I, while those who were not prescribed ASA were assigned to Cohort II. Moreover, patients diagnosed with HNC, and prescribed ASA were assigned to Cohort III, while those with HNC but no history of ASA use were assigned to Cohort IV.Results: After matching, Cohorts I and II included 5,716,056 patients each. HNC incidence was significantly lower (OR 0.88; 95% CI 0.86–0.90) in Cohort I (+ASA) compared to Cohort II (−ASA). Furthermore, five-year survival was higher for patients taking ASA medication (survival probability 67.93%) compared to patients who did not (65.54%). These findings coincide with a lower risk of death of 22.8% (+ASA) compared to 23.6% (−ASA), which was statistically significant (p= 0.006). Patients with ASA intake also showed a lower risk of malignant neoplasms of lymph nodes (17.4% vs. 18.5%).Conclusions: Our analyses revealed a lower risk of HNC, a higher five-year survival rate, and a lower risk of malignant neoplasms of lymph nodes in patients with ASA medication. However, the retrospective design and the lack of evaluation of confounders limit the significance of our data, and, therefore, further analyses should be considered.
背景/目的：已有研究表明乙酰水杨酸（ASA）药物对癌症风险和生存率具有积极影响。为此，本回顾性病例对照研究通过对超过1100万患者的数据分析，探讨ASA与头颈部癌（HNC）之间的关联，重点考察ASA摄入对HNC发病风险、五年生存率以及继发恶性肿瘤和恶性淋巴结转移可能性的影响。方法：回顾性临床数据来源于联邦电子健康记录网络。服用ASA处方的患者纳入队列I，未服用者纳入队列II；确诊HNC且服用ASA的患者纳入队列III，确诊HNC但无ASA用药史者纳入队列IV。结果：匹配后队列I与队列II各纳入5,716,056例患者。与队列II（-ASA）相比，队列I（+ASA）的HNC发病率显著降低（OR 0.88；95% CI 0.86–0.90）。此外，服用ASA患者的五年生存率（生存概率67.93%）高于未服用者（65.54%）。这一结果与死亡风险降低趋势一致（+ASA组22.8% vs -ASA组23.6%），差异具有统计学意义（p=0.006）。ASA用药患者同时表现出更低的淋巴结恶性肿瘤风险（17.4% vs 18.5%）。结论：本研究提示ASA用药可降低HNC发病风险、提高五年生存率并减少淋巴结恶性肿瘤发生风险。但回顾性研究设计及混杂因素评估的缺失限制了数据的论证强度，需进一步开展深入分析。
肿瘤(癌症)患者之家